Abstract
Lisdexamfetamine dimesylate (Vyvanse; New River Pharmaceuticals/Shire), a prodrug of D-amphetamine, was approved by the US FDA in February 2007 for the treatment of attention-deficit/hyperactivity disorder.
| Original language | English |
|---|---|
| Pages (from-to) | 343-344 |
| Number of pages | 2 |
| Journal | Nature Reviews Drug Discovery |
| Volume | 6 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2007 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Lisdexamfetamine dimesylate'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver